Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (“Lattice
Biologics” or the “Company”) today announced that it plans to
evaluate its amniotic fluid concentrate, AmnioBoost, in patients
with acute respiratory distress syndrome (ARDS) caused by
coronavirus (COVID-19)
AmnioBoost has potential for use in the treatment of ARDS, which
is the principal cause of death in COVID-19 infection.1 Mortality
in COVID-19 infected patients with the inflammatory lung condition
(ARDS) is reported to approach 50%, and is associated with older
age, co-morbidities such as diabetes, higher disease severity, and
elevated markers of inflammation.1 Current therapeutic
interventions do not appear to improve in-hospital survival.1
AmnioBoost is believed to have immunomodulatory properties to
counteract the inflammatory processes that are implicated in
several diseases by down-regulating the production of
pro-inflammatory cytokines, increasing production of
anti-inflammatory cytokines, and enabling recruitment of naturally
occurring anti-inflammatory cells to involved tissues.
Major anti-inflammatory cytokines found in AmnioBoost include:
interleukin (IL)-1beta, IL-1ra, TNF-alpha, IL-6, IL-8, IL-16, CCL2,
CXCL7, MIF, and GRO a/b/g. Specific cytokine receptors for IL-1,
and tumor necrosis factor-alpha, function as proinflammatory
cytokine inhibitors.
This is supported by recently published results from an
investigator-initiated clinical study conducted in China which
reported that allogeneic mesenchymal stem cells (MSCs) cured or
significantly improved functional outcomes in all seven treated
patients with severe COVID-19 pneumonia.2
AmnioBoost
AmnioBoost was originally developed for chronic adult
inflammatory conditions such as osteoarthritis, but has found
multiple uses in the treatment of bone and cartilage repair, as
well as soft tissue repair. It is an investigational therapy
comprising concentrated allogeneic MSCs and cytokines derived from
amniotic fluid.
The amniotic fluid is donated from non-related, healthy mothers
and recovered by caesarian section; the baby is not harmed in any
way. Additionally, AmnioBoost has been injected in over 1,000
patients with no adverse events, and appears to be well
tolerated.
References
1. Liu Y et al. Clinical features and progression of acute
respiratory distress syndrome in coronavirus disease 2019. Medrxiv
2020; https://doi.org/10.1101/2020.02.17.20024166 2. Leng Z, et al.
Transplantation of ACE2- Mesenchymal Stem Cells Improves the
Outcome of Patients with COVID-19 Pneumonia[J]. Aging and Disease,
10.14336/AD.2020.0228
About Lattice Biologics Ltd.:
Lattice Biologics is traded on the TSX-V under the symbol: LBL.
The Company is an emerging leader in the field of cellular
therapies and tissue engineering, with a focus on dental
indications.
Lattice Biologics develops and manufactures biologic products to
domestic and international markets. The Company’s products are used
in a variety of surgical applications.
Lattice Biologics maintains its headquarters, laboratory and
manufacturing facilities in Belgrade, Montana as well as offices in
Phoenix, Arizona. The facility includes ISO Class 1000 clean rooms,
and specialized equipment capable of crafting traditional
allografts and precision specialty allografts for various clinical
applications. The Lattice Biologics team includes highly trained
tissue bank specialists, surgical technicians, certified sterile
processing and distribution technicians, and CNC operators who
maintain the highest standards of aseptic technique throughout each
step of the manufacturing process. From donor acceptance to the
final packaging and distribution of finished allografts, Lattice is
committed to maintaining the highest standards of allograft
quality, innovation, and customer satisfaction.
Lattice Biologics maintains all necessary licensures to process
and sell its tissue engineered products within the U.S. and
internationally. This includes Certificates to Foreign Governments
from the U.S. Food and Drug Administration (FDA) and registrations
for multiple countries, which allow the export of bone, tendon,
meniscus, ligament, soft tissue, and cartilage products outside of
the U.S.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Cautionary Statement on Forward-Looking Information:
Certain information contained in this news release constitutes
“forward-looking statements” within the meaning of the ‘safe
harbour’ provisions of Canadian securities laws. All statements
herein, other than statements of historical fact, are to be
considered forward looking. Generally, forward-looking information
can be identified by the use of forward-looking terminology such as
“planned”, “potential”, “future”, “expected”, “could”, “possible”,
“goal”, “intends”, “will” or similar expressions. Forward-looking
statements in this news release include, without limitation:
information pertaining to the Company’s strategy, plans, or future
financial performance, such as statements with respect to the
Transaction, and other statements that express management’s
expectations or estimates of future performance. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, level of activity,
performance or achievements of Lattice to be materially different
from those expressed or implied by such forward-looking
statements.
Forward-looking statements are necessarily based upon a number
of factors and assumptions that, while considered reasonable by
management as of the date such statements are made, are inherently
subject to significant business, economic and competitive
uncertainties and contingencies. The factors and assumptions that
could prove to be incorrect, include, but are not limited to: that
market prices will be consistent with expectations, the continued
availability of capital and financing, and that general economic,
market and business conditions will be consistent with
expectations. The forward-looking statements are not guarantees of
future performance. We disclaim any obligation to update or revise
any forward-looking statements, except as required by law. Readers
are cautioned not to put undue reliance on these forward-looking
statements.
United States Advisory: The securities referred to herein have
not been and will not be registered under the United States
Securities Act of 1933, as amended (the "U.S. Securities Act"), and
may not be offered, sold, or resold in the United States or to, or
for the account of or benefit of, a U.S. Person (as such term is
defined in Regulation S under the U.S. Securities Act) unless an
exemption from the registration requirements of the U.S. Securities
Act is available. This press release shall not constitute an offer
to sell or the solicitation of an offer to buy any securities, nor
shall there be any sale of securities in the state in the United
States in which such offer, solicitation or sale would be
unlawful.
Subscribe to Lattice
News Updates Follow us on Twitter: @LatticeBio
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200313005049/en/
Guy Cook, CEO Lattice Biologics Ltd. 480-563-0800 Office
News@LatticeBiologics.com www.LatticeBiologics.com
Lattice Biologics (TSXV:LBL)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Lattice Biologics (TSXV:LBL)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
